Samtidig brug af stoffer, som metaboliseres ved CYP450- isoformer, kan give højere eller lavere plasmaniveauer af enten masitinib eller disse stoffer.
Concurrent use of substances which are metabolised by CYP450 isoforms may result in higher or lower plasma levels of either masitinib or those substances.